Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathing Machine's impact on key muscle under scrutiny in COPD study

NCT ID NCT07193017

Knowledge-focused Sponsor: Istanbul Demiroglu Bilim University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how long-term use of a BiPAP machine affects the diaphragm—the main breathing muscle—in people with advanced COPD. Researchers will use ultrasound to measure diaphragm thickness and movement over 6 weeks and 12 months in 30 patients. The goal is to learn whether BiPAP helps or harms diaphragm function, which could guide future treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Biphasic positive airway pressure (BiPAP) device
What this could lead to
If successful, this could help doctors understand how BiPAP affects the diaphragm in COPD, potentially leading to better treatment plans for advanced respiratory failure.
What could go wrong
This is a small, early-stage observational study with only 30 participants, so results may not apply to all COPD patients. It measures changes but does not test a new drug or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

COPD patient prescribed BIPAP

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being between 40-80 years of age, * Having a diagnosis of stable COPD for at least 1 year, * Being in a stable phase (no acute exacerbation within the last 4 weeks), * Meeting the GOLD 2025 A-B-E classification according to symptoms and exacerbation history, * Having been initiated on BiPAP therapy with a clinical indication, * Being willing to participate in the study and providing informed consent. Exclusion Criteria: * Pregnancy, * Diaphragmatic paralysis, * Neuromuscular and neurological diseases, * Decompensated heart failure, * Chest deformity, * Acute exacerbation within the last month, * Pneumothorax, * Body mass index greater than 35 kg/m², * Long-term corticosteroid use, * Chemotherapy, * Active malignancy, * Inability to cooperate, * Thoracoabdominal surgery within the last 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipap biphasic intermittent positive airway pressure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset diaphragm disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipap biphasic intermittent positive airway pressure COPD (chronic obstructive pulmonary disease) Diaphragm issues Ultrasound diagnostics

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Demiroglu Bilim University, Department of Physiotherapy and Rehabilitation

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.